Woodline Partners’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
Other funds holding RCUS
Woodline Partners's RCUS Position: Q3 2026 in Review
Woodline Partners reduced its Arcus Biosciences (RCUS) stake by 5.1% in Q3 2026, selling an estimated $4.31M and leaving 2,854,798 shares worth $73.7M. The position accounts for 0.22% of the portfolio, ranked #98.
Woodline Partners first reported a position in RCUS in Q1 2020 and has held it in 21 quarters since. The position peaked at $92.7M in Q2 2026. 244 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.
- Woodline Partners held 2,854,798 shares of Arcus Biosciences worth $73.7M as of Q3 2026.
- Woodline Partners sold 153,000 Arcus Biosciences shares in Q3 2026, an estimated $4.31M.
- Arcus Biosciences made up 0.22% of Woodline Partners's portfolio in Q3 2026, its #98 holding.
- Woodline Partners first reported a position in Arcus Biosciences in Q1 2020 and has held it in 21 quarters since.
- Woodline Partners's Arcus Biosciences position peaked at $92.7M in Q2 2026.
- 244 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.